AQST Q3 2021 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$427M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$13M+60.9% YoY

Gross Profit

$9M66.9% margin

Operating Income

-$8M-60.0% margin

Net Income

-$15M-109.5% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

-13.4%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$65M

Total Liabilities

$126M

Stockholders' Equity

-$60M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$8M	+60.9%
Gross Profit	$9M	$5M	+68.3%
Operating Income	-$8M	-$14M	+42.2%
Net Income	-$15M	-$17M	+12.1%

Revenue Segments

Manufacture and Supply Revenue

$10M79%

Proprietary Product Sales

$2M15%

Co-Development and Research Fees

$523,0004%

License and Royalty Revenue

$328,0002%

Geographic Segments

UNITED STATES

$11M79%

Non-US

$3M21%